Clinical trials: Advanced Nasopharyngeal Carcinoma
Locally Advanced Nasopharyngeal Carcinoma
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
This phase III trial aims to evaluate the efficacy and safety of induction chemotherapy combined with serplulimab (induction/maintenance therapy) with omission of concurrent chemotherapy in patients with locally advanced…
- Trial name
- NCT07177443
- Testing
- Radiotherapy, Serplulimab, Cisplatin
- Where
- China
- Volunteers
- 710 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Nasopharyngeal Cancinoma (NPC)
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
Based on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified.
- Trial name
- NCT07496190
- Testing
- Becotatug vedotin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx
Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00049283
- Testing
- erlotinib hydrochloride, docetaxel, radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Two different patient populations will be targeted for this study. The first population (SP1) will include patients with recurrent/metastatic head and neck cancers, excluding salivary gland carcinomas.
- Trial name
- NCT00228488
- Testing
- Gefitinib
- Where
- 2 sites in Hong Kong, Singapore
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Nasopharyngeal Carcinoma
S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
This study is a prospective phase II trial which is designed to evaluate the efficacy and safety of IMRT combined with S-1 CCRT for locally advanced NPC.
- Trial name
- NCT03668366
- Testing
- S-1
- Where
- China
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Fudan University
Nasopharyngeal Cancer
Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel, cisplatin (DDP) and 5-fluorouracil (5-Fu)…
- Trial name
- NCT04850235
- Testing
- Nab paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT02786641
- Testing
- Docetaxel, Cisplatin 1, Xeloda
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.
The purpose of this study is to evaluate the efficacy and safety of chemotherapy with Lobaplatin and 5-FU, in Recurrent Local or Distant Advanced Nasopharyngeal Carcinoma.
- Trial name
- NCT03210389
- Testing
- Lobaplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients
Malnutrition is very common in locally advanced nasopharyngeal carcinoma(NPC) patients undergoing current chemoradiotherapy (CRT) due to dysphagia, mucositis, nausea and other treatment-related problems.
- Trial name
- NCT02776124
- Testing
- Healing Elements,Methuselah Medical Technology
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Drug Use for Unapproved Schedule
EBV Positive Nasopharyngeal Carcinoma Treated With Concurrent Chemo-radiotherapy With or Without Anti-Viral Drug
PCR-DNA of EBV test is a good prognostic indicator for survival after treatment (report: Prognostic Impact of Plasma, Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation…
- Trial name
- NCT03656965
- Testing
- Acyclovir 800 MG, Radiotherapy and chemotherapy
- Where
- Kuwait
- Volunteers
- 50 people
- Sponsor
- Kuwait Cancer Control Center
Nasopharyngeal Neoplasms
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial plans to enroll 40 patients with stage III-IVA (AJCC 8th, except T3N0-1 or T4N0) locoregionally-advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT03619824
- Testing
- Sintilimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Patients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
- Trial name
- NCT04227509
- Testing
- Pembrolizumab
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Head and Neck Cancer
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083057
- Testing
- gefitinib, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Nasopharyngeal Carcinoma
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
- Trial name
- NCT05979961
- Testing
- IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
- Where
- 8 sites in China
- Volunteers
- 464 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Advanced Nasopharyngeal Carcinoma
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
Mainly compared with GP induction chemotherapy combined with IMRT and TPF induction chemotherapy combined with IMRT in the treatment of nasopharyngeal carcinoma, the cure rate, remission rate, treatment of distant metastases and…
- Trial name
- NCT03723343
- Testing
- GP+IMRT, TPF+IMRT
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Guiyang Medical University
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
The purpose of this study is to investigate how effective the study drug IPI-549 is against types of cancers. IPI-549 is considered experimental because it is not approved by the US Food and Drug Administration (FDA) for the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV
- Trial name
- NCT03795610
- Testing
- IPI-549
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Assuntina G. Sacco, MD
Metastatic Solid Tumors, Non-small Cell Lung Cancer
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
This is a first-in-human, open-label, nonrandomized, four-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX-105 and INBRX-105 in combination…
- Conditions
- Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- PDL1x41BB (NCT03809624)
- Testing
- INBRX-105 - PDL1x41BB antibody, Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Inhibrx Biosciences, Inc
Head and Neck Cancer
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them.
- Trial name
- NCT00301028
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma, Neoadjuvant Therapy
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced…
- Conditions
- Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
- Trial name
- NeoTurbo (NCT05340270)
- Testing
- PD-1 inhibitor+GP, GP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University